{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 1b\/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination with Elranatamab in Participants with Relapsed and\/or Refractory Multiple Myeloma","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-1b-2a-multicenter-open-label-study-to-determine-the-recommended-dose-and-schedule-and-evaluate-the-safety-and-preliminary-efficacy-of-mezigdomide-in-combination-with-elranatamab-in-particip\/#breadcrumbitem"}]}